This is a working overview of pentadecapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
=== Protection against cardiovascular disease === There is evidence that garlic may prevent the development of cardiovascular diseases. A possible reason for some of these diseases, such as atherosclerosis or coronary heart disease is oxidative stress. The latter is reduced by diallyl disulfide by assisting in the detoxification of the cell, as well as some other mechanisms. By activating the TRPA1 ion channel, diallyl disulfide leads to a short-term lowering of blood pressure.
An N-terminal KOW-like domain A central OB domain, which forms an oligonucleotide-binding (OB)-fold. It is not clear if this region is involved in binding nucleic acids A C-terminal domain which adopts an OB-fold, with five beta-strands forming a beta-barrel in a Greek-key topology Eukaryotes and archaea lack EF-P. In these domains, a similar function is performed by the archaeo-eukaryotic initiation factor, a/eIF-5A, which exhibits some modest sequence and structural similarity with EF-P. There are, however, important differences between EF-p and eIF-5A. (a) EF-P has a structure similar to that of L-shaped tRNA and it contains three (I, II and III) β-barrel domains. In contrast, eIF-5A contains only two domains (C and N) with a corresponding size difference. (b) Moreover, as opposed to eIF-5A, which contains the non-proteinogenic amino acid hypusine that is essential for its activity, EF-P displays a diversity of post-transcriptional modifications at the analogous position (β-lysylation of lysine residue, rhamnosylation of arginine residue, or none at all).
== Veterinary use == Based on a 2010 review of injectable-agent use for short-duration anesthesia, the American Association of Equine Practitioners recommends the use of xylazine as a sedative for induction of anesthesia for durations of around 20 minutes or less. In addition, diazepam and ketamine are recommended after the xylazine. For longer duration anesthesia, those over 30 minutes, the most common anesthetics is the combination of guaifenesin, ketamine, and xylazine or isoflurane.
Sources: en.wikipedia.org
=== Real-time cell-binding === In this type of assay the binding of a ligand to cells is followed over time. The obtained signal is proportional to the number of ligands bound to a target structure, often a receptor, on the cell surface. Information about the ligand-target interaction is obtained from the signal change over time and kinetic parameters such as the association rate constant ka, the dissociation rate constant kd and the affinity KD can be calculated. By measuring the interaction directly on cells, no isolation of the target protein is needed, which can otherwise be challenging, especially for some membrane proteins. To ensure that the interaction with the intended target structure is measured appropriate biological controls, such as cells not expressing the target structure, are recommended. Real-time measurements using label-free or label-based approaches have been used to analyze biomolecular interactions on fixated or on living cells. The advantage of measuring ligand-receptor interactions in real-time, is that binding equilibrium does not need to be reached for accurate determination of the affinity.
bans on arms-related exports, controls over dual-use technology exports, restrictions on economic assistance, financial restrictions such as: authority to prohibit U.S. citizens from engaging in financial transactions with listed individuals, entities, or governments, except by license from the U.S. government, requiring the United States to oppose loans by the World Bank and other international financial institutions, diplomatic immunity waived, to allow families of terrorism victims to file for civil damages in U.S. courts, tax credits for companies and individuals denied for income earned in listed countries, duty-free goods exemption suspended for imports from those countries, and prohibition of U.S. Defense Department contracts above $100,000 with companies controlled by listed countries, visa restrictions preventing certain individuals from entering the U.S.
Beginning in 1986, members of the University Health Center including Presbyterian University Hospital, Falk Clinic, the Pittsburgh Cancer Institute and Eye & Ear Hospital consolidated into the Medical and Health Care Division (MHCD) and led by Detre, became closely linked administratively, although Presbyterian University Hospital remained separate. In 1990, MHCD acquired neighboring Montefiore Hospital which merged with Presbyterian University Hospital to form the "University of Pittsburgh Medical Center" (shortened to UPMC), the first time that name was officially used. UPMC then formed a network of specialty and community hospitals in 1994 named the Tri-State Health System and established a for-profit health insurance division, UPMC Health Plan, which contracted with these hospitals. In 1996, UPMC acquired South Side, Aliquippa and Braddock hospitals. Meanwhile, UPMC began to merge with several of the already affiliated Tri-State hospitals including St. Margaret Memorial, Shadyside, and Passavant hospitals in 1997 and Magee-Womens Hospital in 1998. The acquisition and mergers consolidated the Tri-State Health System into a significant portion of the UPMC health system. Due to the immense growth of the medical center, as well as the university's concerns over financial risks associated with faculty practice in the face of national changes in health care reimbursement, the University of Pittsburgh and UPMC separated in 1998, launching UPMC as an independent nonprofit corporation supporting the university.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.